ClinicalTrials.gov record
Completed Phase 1 Interventional

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

ClinicalTrials.gov ID: NCT02903069

Public ClinicalTrials.gov record NCT02903069. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 4:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1b, Multicenter, Open-Label Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed WHO Grade IV Malignant Glioma

Study identification

NCT ID
NCT02903069
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Celgene
Industry
Enrollment
66 participants

Conditions and interventions

Interventions

  • MRZ Drug
  • Optune Device
  • RT Radiation
  • TMZ Drug

Drug · Device · Radiation

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 16, 2016
Primary completion
Jan 24, 2021
Completion
Jan 24, 2021
Last update posted
Apr 18, 2021

2016 – 2021

United States locations

U.S. sites
6
U.S. states
4
U.S. cities
6
Facility City State ZIP Site status
University of California San Diego Medical Center La Jolla California 92037
UC Irvine Orange California 92868
John Wayne Cancer Center Outpatient Clinic Santa Monica California 90404
Northwestern Center For Clinical Research Chicago Illinois 60611
Duke Cancer Center Durham North Carolina 27710
Pennsylvania State University College of Medicine Hershey Pennsylvania 17033

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02903069, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 18, 2021 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02903069 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →